Kite Car T therapy Yescarta bags FDA approval for type of lymphatic cancer
October 19, 2017 No Comment
Yescarta FDA approval : Kite Pharma has bagged the US FDA approval for its chimeric antigen receptor T cell (CAR T) therapy Yescarta (axicabtagene ciloleucel) for a type of lymphatic cancer (Lymphoma). FDA Approves New Lymphoma Drug Yescarta The Car T therapy from the Gilead subsidiary will be available as a new treatment option in […]
Continue reading …AstraZeneca lung cancer drug Tagrisso gets FDA breakthrough therapy designation
October 15, 2017 No Comment
Pharma news updates : Tagrisso (osimertinib), the AstraZeneca lung cancer drug has bagged the breakthrough therapy designation (BTD) from the US FDA for the treatment of non-small cell lung cancer (NSCLC) in a first line setting. The BTD designation for the AstraZeneca cancer drug is specifically for treating metastatic NSCLC patients who have tested positive […]
Continue reading …
Luxturna FDA approval news : Luxturna (voretigene neparvovec), a gene therapy from Spark Therapeutics is closing in towards an FDA approval for treating blindness due to an inherited retinal disease (IRD), following the recommendation from an advisory panel of the US drug regulator. An adeno-associated viral (AAV) vector gene therapy, Luxturna has been recommended to […]
Continue reading …Novo Nordisk bags insulin aspart injection Fiasp FDA approval for diabetes
October 2, 2017 No Comment
Fiasp FDA approval : Danish pharmaceutical company Novo Nordisk has secured the US FDA approval for its new fast-acting mealtime insulin aspart injection Fiasp 100 Units/mL for diabetes treatment in adults. Already approved in Canada and Europe, Fiasp is the addition of two excipients to Novo Nordisk’s insulin aspart (NovoLog) in a new formulation with […]
Continue reading …Abemaciclib FDA approval : Lilly breast cancer drug gets regulatory nod
September 30, 2017 No Comment
Abemaciclib FDA approval : Eli Lilly and Company (Lilly) has secured the US FDA approval for Verzenio (abemaciclib) to treat metastatic breast cancer in patients whose disease had progressed after a prior treatment. Abemaciclib FDA Approval The breast cancer drug approval is for patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 […]
Continue reading …Ajanta Pharma gets USFDA approval for Entacapone, Parkinson’s disease tablet
September 4, 2017 No Comment
Ajanta Pharma got the final USFDA approval for Entacapone tablets which is used for treating the Parkinson’s disease. Ajanta Pharma said that it has received the final approval for Entacapone tablets from US FDA in a BSE filing. Entacapone tablets are bioequivalent generic version of Comtan tablets. Ajanta Pharma company said that they will launch […]
Continue reading …
Danish pharma firm Novo Nordisk has secured the approval from the U.S. Food and Drug Administration (FDA) for using its diabetes drug Victoza (liraglutide) to treat heart diseases associated with type 2 diabetes. The Novo Nordisk diabetes drug Victoza can now be used in the US to decrease the risk of major adverse cardiovascular (CV) […]
Continue reading …
Genentech’s injection to treat diabetic retinopathy, lucentis (ranibizumab injection) has been approved by the U.S. Food and Drug Administration (FDA). The approved dosage of ranibizumab injection to be administered monthly once is 0.3mg for treating all types of diabetic retinopathy. Diabetic Retinopathy Treatment with Lucentis Injection Lucentis FDA approval means that the drug is now […]
Continue reading …
The Indian FDA (CDSCO – Central Drugs Standard Control Organization) has granted a commercial license to APAC Biotech to market Apceden, a Dendritic cell-based autologous Immuno-oncology drug for prostate, ovarian, colo-rectal and non small cell lung carcinoma form of cancers. Following a stringent review of the application submitted by the Indian biotechnology company, the Indian […]
Continue reading …Pfizer’s blood cancer drug inotuzumab ozogamicin gets FDA priority review
February 23, 2017 No Comment
Pfizer’s blood cancer drug, inotuzumab ozogamicin has secured a priority review designation from the US Food and Drug Administration (FDA). Inotuzumab ozogamicin has been developed as an anti-CD22 antibody-drug conjugate to treat patients suffering from acute lymphoblastic leukemia (ALL) whether the disease has recurred or in refractory form. As of now, the blood cancer drug […]
Continue reading …
Business News Today
- JCPenney seeks bankruptcy protection amid Covid-19 disruption
- 7-Eleven rolls out ready-to-bake pizza, tenders, wings, and taquitos
- Eramet to sell TiZir smelting plant in Norway to Tronox for $300m
- AI-based learning platform Quizlet raises $30m in Series C round
- Commonwealth Bank of Australia to sell 55% stake in Colonial First State to KKR
- Kellogg’s launches Kellogg’s JUMBO SNAX to bring cereals in jumbo size packs
- SSR Mining to acquire US gold producer Alacer Gold for $1.72bn
- SBI General Insurance introduces Arogya Sanjeevani Health Insurance Policy
- Latitude 27 Capital acquires jewelry components manufacturer JK Findings
- Core Project phase 1 in North Sea : Subsea 7 wins EPCI contract from IOG
